CANY
DRNA

Caxton Associates (New York)’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Caxton Associates (New York)’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-24,733
Closed -$628K – 566
2020
Q2 		$628K Buy
24,733
+12,311
+99% +$265K 0.05% 107
2020
Q1 		$228K Sell
12,422
-11,566
-48% -$225K 0.04% 321
2019
Q4 		$528K Buy
+23,988
New +$483K 0.07% 168

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Caxton Associates (New York)'s DRNA Position: Q3 2020 in Review

Caxton Associates (New York) sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 24,733 shares — an estimated $628K sold.

Caxton Associates (New York) first reported a position in DRNA in Q4 2019 and held it in 3 quarters. The position peaked at $628K in Q2 2020. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

  • Caxton Associates (New York) reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Caxton Associates (New York) sold 24,733 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $628K.
  • Caxton Associates (New York) first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 3 quarters.
  • Caxton Associates (New York)'s Dicerna Pharmaceuticals, Inc. position peaked at $628K in Q2 2020.
  • 172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on Caxton Associates (New York)'s 13F filing for Q3 2020, filed 16 Nov 2020.